Showing results (1-10 of 132) with videos related to
Sort By:
Pageof 14
Current Neuropharmacology|February 24, 2017
Beyond Ketamine: New Approaches to the Development of Safer AntidepressantsShigeyuki ChakiTrends in Pharmacological Sciences|April 18, 2017
mGlu2/3 Receptor Antagonists as Novel AntidepressantsShigeyuki ChakiAdvances in Pharmacology (San Diego, Calif.)|August 6, 2019
mGlu2/3 receptor antagonistsShigeyuki ChakiAdvances in Pharmacology (San Diego, Calif.)|July 4, 2020
mGlu2/3 receptor as a novel target for rapid acting antidepressantsShigeyuki ChakiNihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology|September 28, 2012
[The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant]Shigeyuki ChakiPharmacology, Biochemistry, and Behavior|July 6, 2024
Melanin-concentrating hormone receptor: A therapeutic target for novel anxiolyticsShigeyuki ChakiThe International Journal of Neuropsychopharmacology|March 18, 2021
Vasopressin V1B Receptor Antagonists as Potential AntidepressantsShigeyuki ChakiEuropean Journal of Pharmacology|April 8, 2010
Group II metabotropic glutamate receptor agonists as a potential drug for schizophreniaShigeyuki ChakiPsychopharmacology|March 28, 2025
Orexin receptors: possible therapeutic targets for psychiatric disordersShigeyuki ChakiNeuropharmacology|November 24, 2022
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic systemShigeyuki Chaki, Mai WatanabePageof 14